Bioprocessing Postdoctoral Fellowship Position

Organization
National Institutional Institute of Standards and Technology
Job Location
Gaithersburg, MD 20899
Salary
65,000
Job Description

A government research position is open to U.S. citizens for 2 years at the National Institute of Standards and Technology campus in Gaithersburg, MD. The project will be done in close collaboration with a major biopharmaceutical company (MedImmune) also located in Gaithersburg, MD. The project is to study the genomic stability of Chinese hamster ovary (CHO) cell lines during large-scale production of biopharmaceuticals. The goals of the project are measure the changes in the genomes of CHO cells that occur during prolonged passaging in culture that may led to changes in the expression of recombinant proteins. Sensitive methods including microarrays, sequencing, quantitative PCR and droplet digital PCR will be developed to detect genomic changes to accurately monitor changes during production of therapeutic proteins. The candidate should be experienced in the quantitative methods for the measurements of DNA and RNA, such as microarrays, next gen sequencing, quantitative PCR, and digital PCR. Skill and experience in bioinformatics analysis of genomic and transcriptomics is desirable.   Associates will be employees of NIST, a non-regulatory federal agency within the U.S. Department of Commerce, and US Citizenship is required.  The appointments will be for 2 years at a salary of $65,000 USD per year along with an attractive benefits package.  Contact: Kenneth Cole, [email protected] 301-975-2169

How to Apply

Send C.V. to Kenneth Cole at [email protected]

A research duo finds that science and technology graduate students who turn away from academic careers do so because of changes in their own interests.

Students whose classmates are interested in science are more likely to think about a career in science, technology, engineering, and mathematics, a new study says.

CNBC reports that the genetic counseling field is expected to grow as personalized medicine becomes more common.

Gladys Kong writes at Fortune that her STEM background has helped her as a CEO.